

May 1, 2023  
Web Announcement 3064

## Drug Use Review (DUR) Board Approves Changes Effective May 1, 2023.

The Nevada Medicaid Drug Use Review (DUR) Board met on January 19, 2023 and voted to adopt the following changes effective May 1, 2023:

Drug Class/Program	Changes
Respiratory and Allergy Biologics	Updates to existing clinical criteria for Nucala® (mepolizumab) and Dupixent® (dupilumab)
Chelating Agents	Addition of new clinical criteria to penicillamine
Vitamin D Analogs	Addition of new clinical criteria to Rayaldee® (calcifediol)
Amyotrophic Lateral Sclerosis (ALS) Agents	Addition of new clinical criteria to Relyvrio® (sodium phenylbutyrate/taurursodiol)
pegfilgrastim	Updates to existing clinical criteria
darbepoetin alfa	Updates to existing clinical criteria
denosumab	Updates to existing clinical criteria
ocrelizumab	Updates to existing clinical criteria

Prior Authorization forms may be found on the below webpages:

<https://nevadamedicaid.magellanrx.com/provider/forms> (pharmacy/point-of-sale)

<https://www.mrxgateway.com/> (medical pharmacy/physician administered drugs)